MedTrace Logo

Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET

NCT00188149 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2005-12-29

No results posted yet for this study

Summary

Prognosis of patients with Hodgkin´s lymphoma (HL) has been improved significantly over the last decade. Therefore, the impact of treatment associated long-term toxicities and late effects such as second cancers increased. The purpose of this prospective multicenter trial is to show the feasibility of the treatment with ABVD alone in patients with limited stage (HL1) and intermediate stage (HL2) disease and of an intensified etoposide-free chemotherapy regimen for patients with advanced disease (HL3) including 18F-FDG-PET evaluation.

Conditions

  • Hodgkin Disease

Interventions

DRUG

Combined chemotherapy (ABVD, BACOPP-D)

PROCEDURE

Radiation therapy

Sponsors & Collaborators

  • Technische Universität Dresden

    collaborator OTHER

  • University Hospital Carl Gustav Carus

    lead OTHER

Principal Investigators

  • Ralph Naumann, MD · University Clinic "Carl Gustav Carus" Dresden

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Completion
2007-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00188149 on ClinicalTrials.gov